Tikva Allocell Pte Ltd
Tikva Allocell develops allogeneic Epstein-Barr virus-specific T cell therapies to target difficult-to-treat cancers, utilizing proprietary technologies to enhance T cell efficacy and persistence. The company addresses the need for safe, effective, and affordable off-the-shelf cancer treatments, providing accessible options for patients battling the disease.
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Many cancers are difficult to treat with existing therapies, creating a need for more effective and accessible treatment options, particularly those that can target solid tumors and overcome the limitations of current approaches. Developing safe, effective, and affordable "off-the-shelf" T cell therapies remains a significant challenge.
Solution
Tikva Allocell is developing allogeneic Epstein-Barr virus-specific T cell (ALLO EBVST) therapies designed to target difficult-to-treat cancers. The company leverages a proprietary, IP-protected platform to enhance T cell efficacy, persistence, and safety. Their approach focuses on solid tumor targets and incorporates diverse strategies, including oncolytic viruses to modify the tumor microenvironment and further improve T cell efficacy. The goal is to create readily available and affordable "off-the-shelf" T cell therapies with an excellent safety profile.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers, particularly solid tumors, and the healthcare providers who treat them.
Features
- Allogeneic EBVST platform with enhanced efficacy, persistence, and safety
- Focus on solid tumor targets with unmet medical needs
- Oncolytic virus approach to modify the tumor microenvironment and improve T cell efficacy
- Second-generation Allo EBVST platform